Buckhead Capital Management LLC Buys 2,748 Shares of Becton, Dickinson and Company (NYSE:BDX)

Buckhead Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 31.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,553 shares of the medical instruments supplier's stock after acquiring an additional 2,748 shares during the quarter. Buckhead Capital Management LLC's holdings in Becton, Dickinson and Company were worth $2,646,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock valued at $18,808,000 after acquiring an additional 27,581 shares during the period. Foster Victor Wealth Advisors LLC bought a new stake in Becton, Dickinson and Company during the 1st quarter valued at $6,406,000. GAMMA Investing LLC boosted its position in Becton, Dickinson and Company by 29.9% during the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after acquiring an additional 748 shares during the period. Finally, Ritholtz Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at $224,000. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $2.04 during trading on Friday, hitting $178.86. 3,470,594 shares of the company's stock traded hands, compared to its average volume of 2,150,771. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.13 and a quick ratio of 0.64. The company has a market cap of $51.26 billion, a PE ratio of 34.13, a PEG ratio of 1.35 and a beta of 0.25. The firm's fifty day moving average price is $173.51 and its 200 day moving average price is $204.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. During the same period in the prior year, the firm earned $3.17 earnings per share. The company's quarterly revenue was up 4.5% compared to the same quarter last year. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Investors of record on Monday, June 9th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.33%. Becton, Dickinson and Company's dividend payout ratio is currently 79.39%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.36% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Stifel Nicolaus cut their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Barclays decreased their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective on the stock. in a research note on Friday, May 2nd. Finally, Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and reduced their target price for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.